PLB1001

· Beijing Pearl Biotechnology Limited Liability Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for PLB1001, covering 2025-02-06 to 2026-01-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). [Phase 2, Phase 3]

See pricing